Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
N Engl J Med. 2022 Aug 25;387(8):704-714. doi: 10.1056/NEJMoa2201904.
N Engl J Med. 2022.
PMID: 36001711
Clinical Trial.